Evidence map›Paper›PMID 29848024›Full record

ArticleAmerican journal of physiology. Gastrointestinal and liver physiology2018

An enhanced Lactobacillus reuteri biofilm formulation that increases protection against experimental necrotizing enterocolitis.

Jacob K Olson, Jason B Navarro, Jacob M Allen, Christopher J McCulloh, Lauren Mashburn-Warren, Yijie Wang, Vanessa A Varaljay, Michael T Bailey, Steven D Goodman, Gail E Besner

Open access · bronzeAbstract read
In one paragraph

Article in American journal of physiology. Gastrointestinal and liver physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Necrotizing Enterocolitis: What's New and What's Next?International journal of molecular sciences · 2025
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Probiotics: insights and new opportunities forCritical reviews in microbiology · 2023
    Review
  13. Article
  14. Review
  15. The role of potential probiotic strainsFrontiers in microbiology · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Next-Generation Probiotic Therapy to Protect the Intestines From Injury.Frontiers in cellular and infection microbiology · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jacob K OlsonCenter for Perinatal Research, The Research Institute at Nationwide Children's Hospital, Department of Pediatric Surgery, Nationwide Children's Hospital , Columbus, Ohio.
Jason B NavarroCenter for Microbial Pathogenesis, The Research Institute at Nationwide Children's Hospital , Columbus, Ohio.
Jacob M AllenCenter for Microbial Pathogenesis, The Research Institute at Nationwide Children's Hospital , Columbus, Ohio.
Christopher J McCullohCenter for Perinatal Research, The Research Institute at Nationwide Children's Hospital, Department of Pediatric Surgery, Nationwide Children's Hospital , Columbus, Ohio.
Lauren Mashburn-WarrenCenter for Microbial Pathogenesis, The Research Institute at Nationwide Children's Hospital , Columbus, Ohio.
Yijie WangCenter for Perinatal Research, The Research Institute at Nationwide Children's Hospital, Department of Pediatric Surgery, Nationwide Children's Hospital , Columbus, Ohio.
Vanessa A VaraljayCenter for Microbial Pathogenesis, The Research Institute at Nationwide Children's Hospital , Columbus, Ohio.
Michael T BaileyCenter for Microbial Pathogenesis, The Research Institute at Nationwide Children's Hospital , Columbus, Ohio.
Steven D GoodmanCenter for Microbial Pathogenesis, The Research Institute at Nationwide Children's Hospital , Columbus, Ohio.
Gail E BesnerCenter for Perinatal Research, The Research Institute at Nationwide Children's Hospital, Department of Pediatric Surgery, Nationwide Children's Hospital , Columbus, Ohio.
Nationwide Children's Hospital · US

Funding

Tunable Native Probiotic Formulations for the Treatment of NEC.R01GM123482 · NIGMS · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI BAILEY, MICHAEL T, BESNER, GAIL E · 2017 to 2020
$1.8M
A Novel Probiotic Platform to Treat Necrotizing EnterocolitisR41GM122130 · NIGMS · MONON BIOVENTURES, LLC · PI BESNER, GAIL E, GOODMAN, STEVEN D · 2017 to 2017
$331k
NIGMS NIH HHS R01 GM123482NIGMS NIH HHS R41 GM122130
6 · The paper itself

Abstract

One significant drawback of current probiotic therapy for the prevention of necrotizing enterocolitis (NEC) is the need for at least daily administration because of poor probiotic persistence after enteral administration, increasing the risk of the probiotic bacteria causing bacteremia or sepsis if the intestines are already compromised. We previously showed that the effectiveness of Lactobacillus reuteri ( Lr) in preventing NEC is enhanced when Lr is grown as a biofilm on the surface of dextranomer microspheres (DM). Here we sought to test the efficacy of Lr administration by manipulating the Lr biofilm state with the addition of biofilm-promoting substances (sucrose and maltose) to DM or by mutating the Lr gtfW gene (encoding an enzyme central to biofilm production). Using an animal model of NEC, we determined that Lr adhered to sucrose- or maltose-loaded DM significantly reduced histologic injury, improved host survival, decreased intestinal permeability, reduced intestinal inflammation, and altered the gut microbiome compared with Lr adhered to unloaded DM. These effects were abolished when DM or GtfW were absent from the Lr inoculum. This demonstrates that a single dose of Lr in its biofilm state decreases NEC incidence. Importantly, preloading DM with sucrose or maltose further enhances Lr protection against NEC in a GtfW-dependent fashion, demonstrating the tunability of the approach and the potential to use other cargos to enhance future probiotic formulations. NEW & NOTEWORTHY Previous clinical trials of probiotics to prevent necrotizing enterocolitis have had variable results. In these studies, probiotics were delivered in their planktonic, free-living form. We have developed a novel probiotic delivery system in which Lactobacillus reuteri (Lr) is delivered in its biofilm state. In a model of experimental necrotizing enterocolitis, this formulation significantly reduces intestinal inflammation and permeability, improves survival, and preserves the natural gut microflora compared with the administration of Lr in its free-living form.

Indexed as

Enterocolitis, NecrotizingInflammationIntestinesAnimalsAnimals, NewbornBiofilmsDextransDrug Delivery SystemsLimosilactobacillus reuteriMicrospheresProbioticsRatsRats, Sprague-DawleydextranomerDextransbiofilmLactobacillus reuterinecrotizing enterocolitisprobiotics

Identifiers

PMID29848024
PMCPMC6415713
OpenAlexW2807118381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.